ArticleOncotarget2019

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.

Erika J Lampert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.